^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CS5001

    i
    Other names: CS5001, ABL202, LCB71, ABL 202
    Company:
    ABL Bio, CStone Pharma, LigaChem Biosci
    Drug class:
    DNA replication inhibitor, ROR1-targeted antibody-drug conjugate
    Related drugs:
    4ms
    CS5001-101: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas (clinicaltrials.gov)
    P1, N=480, Recruiting, CStone Pharmaceuticals | N=156 --> 480 | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Mar 2026 --> Jun 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    gemcitabine • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • oxaliplatin • vincristine • prednisone • CS5001
    10ms
    CS5001-101: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas (clinicaltrials.gov)
    P1, N=156, Recruiting, CStone Pharmaceuticals | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    CS5001
    almost2years
    A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas (clinicaltrials.gov)
    P1, N=156, Recruiting, CStone Pharmaceuticals | Trial completion date: Mar 2024 --> Jun 2025
    Trial completion date
    |
    CS5001